Effects of Iron Supplements on the Pharmacokinetics of MT-6548

Phase 3 Completed 61 enrolled Tanabe Pharma Corporation

RandomizedCrossoverOpen-labelOther

Summary

The objectives of this study are to investigate the pharmacokinetics and safety of MT-6548 co-administered with iron supplements in healthy male volunteers.

Timeline

Start: 2018-08-27
Primary completion: 2018-09-30
Completion: 2018-09-30

Publications

Results Kokado Y, Kawai K, Nanjo T, Kinoshita S, Kondo K. In Vitro and Clinical Pharmacokinetic Studies of the Effects of Iron-containing Agents on Vadadustat, an Oral Hypoxia-inducible Factor-Prolyl Hydroxylase Inhibitor. Clin Ther. 2021 Aug;43(8):1408-1418.e5. doi: 10.1016/j.clinthera.2021.06.013. Epub 2021 Sep 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Iron supplement A	Unknown	—	Oral
Subject	Iron supplement B	Unknown	—	Oral
Subject	Iron supplement C	Unknown	—	Oral
Subject	Iron supplement D	Unknown	—	Oral
Subject	Vadadustat	Small molecule	150 mg	Oral

Indications

No indication recorded.